Combivent Respimat - (100 mcg/20 mcg per actuation; Spray, metered; Inhalation Aerosol)

Generic Name	Albuterol Sulfate and Ipratropium Bromide	Innovator	Boehringer Ingelheim
Dosage	100 mcg/20 mcg per actuation; Spray, metered; Inhalation Aerosol	Branded US Sales	Less Than $1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	None	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	COMBIVENT RESPIMAT Inhalation Spray is a combination of ipratropium bromide (an anticholinergic agent) and albuterol sulfate (a beta2-adrenergic agonist) indicated for patients with chronic obstructive pulmonary disease (COPD) on a regular aerosol bronchodilator who continue to have evidence of bronchospasm and who require a second bronchodilator.
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
****** ******	*** / *********	*** **, ****	********* ** ****** ** ******	****	******* *** **** *** *** ****

Chronology Of Events